Pfizer Inc (PFE) stock
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3044% above fair value
$28.83−0.62 (-2.11%)
Close on Nov 12, 2026Market cap $164.32BP/E 41.2Yield 5.97%
Pfizer cash
Cash and short-term investments held at the end of each period.
Pfizer's cash was $10.94B at Sep 27, 2026. For fiscal 2025 it was $10.33B, down 13.9% from the year before. Over ten years it grew -7.8% a year on average. The highest annual figure on record is $36.12B in fiscal 2014.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.33B | -13.9% |
| FY2024 | Dec 31, 2024 | $11.99B | +63.8% |
| FY2023 | Dec 31, 2023 | $7.32B | -61.9% |
| FY2022 | Dec 31, 2022 | $19.21B | -19.9% |
| FY2021 | Dec 31, 2021 | $24.00B | +108.1% |
| FY2020 | Dec 31, 2020 | $11.53B | +43.5% |
| FY2019 | Dec 31, 2019 | $8.04B | -57.5% |
| FY2018 | Dec 31, 2018 | $18.92B | -5.8% |
| FY2017 | Dec 31, 2017 | $20.08B | +12.1% |
| FY2016 | Dec 31, 2016 | $17.92B | -23.3% |
| FY2015 | Dec 31, 2015 | $23.36B | -35.3% |
| FY2014 | Dec 31, 2014 | $36.12B | +11.5% |
| FY2013 | Dec 31, 2013 | $32.41B | +0.0% |
| FY2012 | Dec 31, 2012 | $32.40B | +22.5% |
| FY2011 | Dec 31, 2011 | $26.45B | -5.6% |
| FY2010 | Dec 31, 2010 | $28.01B | +7.9% |
| FY2009 | Dec 31, 2009 | $25.97B | +9.4% |
| FY2008 | Dec 31, 2008 | $23.73B | +596.7% |
| FY2007 | Dec 31, 2007 | $3.41B | +86.4% |
| FY2006 | Dec 31, 2006 | $1.83B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $10.94B | -5.0% |
| Q2 FY2026 | Jun 28, 2026 | $8.26B | -26.4% |
| Q1 FY2026 | Mar 29, 2026 | $9.89B | -35.9% |
| Q4 FY2025 | Dec 31, 2025 | $10.33B | -13.9% |
| Q3 FY2025 | Sep 28, 2025 | $11.52B | +43.9% |
| Q2 FY2025 | Jun 29, 2025 | $11.22B | +103.1% |
| Q1 FY2025 | Mar 30, 2025 | $15.43B | +71.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.99B | +63.8% |
| Q3 FY2024 | Sep 29, 2024 | $8.00B | -72.9% |
| Q2 FY2024 | Jun 30, 2024 | $5.52B | -79.4% |
| Q1 FY2024 | Mar 31, 2024 | $9.00B | -50.9% |
| Q4 FY2023 | Dec 31, 2023 | $7.32B | -61.9% |
| Q3 FY2023 | Oct 1, 2023 | $29.48B | +37.0% |
| Q2 FY2023 | Jul 2, 2023 | $26.79B | -2.4% |
| Q1 FY2023 | Apr 2, 2023 | $18.34B | -7.6% |
| Q4 FY2022 | Dec 31, 2022 | $19.21B | -19.9% |
| Q3 FY2022 | Oct 2, 2022 | $21.51B | -27.7% |
| Q2 FY2022 | Jul 3, 2022 | $27.45B | +26.2% |
| Q1 FY2022 | Apr 3, 2022 | $19.85B | +44.8% |
| Q4 FY2021 | Dec 31, 2021 | $24.00B | +108.1% |
| Q3 FY2021 | Oct 3, 2021 | $29.76B | +35.6% |
| Q2 FY2021 | Jul 4, 2021 | $21.75B | -4.8% |
| Q1 FY2021 | Apr 4, 2021 | $13.71B | +31.9% |
| Q4 FY2020 | Dec 31, 2020 | $11.53B | +43.5% |
| Q3 FY2020 | Sep 27, 2020 | $21.95B | +140.0% |
| Q2 FY2020 | Jun 28, 2020 | $22.84B | +76.2% |
| Q1 FY2020 | Mar 29, 2020 | $10.40B | -11.2% |
| Q4 FY2019 | Dec 31, 2019 | $8.04B | -57.5% |
| Q3 FY2019 | Sep 29, 2019 | $9.15B | -47.2% |
| Q2 FY2019 | Jun 30, 2019 | $12.97B | -4.2% |
| Q1 FY2019 | Mar 31, 2019 | $11.70B | +1.4% |
| Q4 FY2018 | Dec 31, 2018 | $18.92B | -5.8% |
| Q3 FY2018 | Sep 30, 2018 | $17.34B | +2.0% |
| Q2 FY2018 | Jul 1, 2018 | $13.54B | -6.0% |
| Q1 FY2018 | Apr 1, 2018 | $11.54B | -21.2% |
| Q4 FY2017 | Dec 31, 2017 | $20.08B | +12.1% |
| Q3 FY2017 | Oct 1, 2017 | $17.00B | – |
| Q2 FY2017 | Jul 2, 2017 | $14.41B | – |
| Q1 FY2017 | Apr 2, 2017 | $14.63B | – |
| Q4 FY2016 | Dec 31, 2016 | $17.92B | – |
See a number that looks wrong?